Skip to Main Content

Paper Details

Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.
Ann Neurol
21
2022
COVID-19, Coronavirus disease 2019, DMT, DMTs, IFN, IL-2, MS, Multiple Sclerosis, N, OCR, Ocrelizumab, Patients, RBD, S1P, SARS-CoV, SARS-CoV-2, SARS-CoV-2 Spike, Sphingosine, Sphingosine 1-phosphate, Sphingosine 1-phosphate receptor, Spike protein, T, T-cell, anti-Spike receptor-binding domain, anti-nucleocapsid, multiple sclerosis, natalizumab, ocrelizumab, patients, severe acute respiratory syndrome-coronavirus 2, women
Author NameAffiliation
Yury PatskovskyLaura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine
Mark J MulliganNYU Grossman School of Medicine
  • 1 - 2

Datasets

Release 1.2